Data Sheet (Cat.No.T7890)

SP-13786

Chemical Properties

CAS No. : 1448440-52-5

Formula: C17H14F2N4O2

Molecular Weight: 344.32

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	SP-13786 is an inhibitor of fibroblast activation protein (FAP) and prolyl oligopeptidase (PREP) with IC50 values of 3.2 nM and 1.8 μM, respectively.
Targets(IC50)	Others,Immunology/Inflammation related,Prolyl Endopeptidase (PREP)
In vivo	**METHODS**: SP-13786 (UAMC-1110) (20 mg/kg, orally, twice a day) was used to treat Panc02-SIY cell tumor xenograft mice, and its effect on tumors in the mice was observed. **RESULTS** Tumor-infiltrating macrophages were reduced during UAMC-1110 administration, and UAMC-1110 significantly increased tumor-infiltrating CD8 T cells, including effector subsets. [2]

Solubility Information

Solubility	DMSO: 250 mg/mL (726.07 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (11.62 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9043 mL	14.5214 mL	29.0428 mL
5 mM	0.5809 mL	2.9043 mL	5.8086 mL
10 mM	0.2904 mL	1.4521 mL	2.9043 mL
50 mM	0.0581 mL	0.2904 mL	0.5809 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jansen K,et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). J Med Chem. 2014 Apr 10;57(7):3053-74.
Gunderson AJ, et al. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. PLoS One. 2019 Feb 6;14(2):e0211117.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481